0001193125-19-277113.txt : 20191029 0001193125-19-277113.hdr.sgml : 20191029 20191029085547 ACCESSION NUMBER: 0001193125-19-277113 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20191029 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191029 DATE AS OF CHANGE: 20191029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 191174596 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d826383d8k.htm 8-K 8-K
false 0000860730 0000860730 2019-10-29 2019-10-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 29, 2019

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

  

001-11239

 

27-3865930

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

     

One Park Plaza, Nashville,

Tennessee

  

37203

(Address of principal executive offices)

  

(Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $.01 par value per share

  

HCA

  

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

Item 2.02. Results of Operations and Financial Condition.

On October 29, 2019, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2019, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On October 29, 2019, the Company issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2019, the text of which is set forth as Exhibit 99.1.

Item 8.01. Other Events.

On October 29, 2019, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.40 per share of the Company’s common stock. The dividend will be paid on December 27, 2019 to stockholders of record at the close of business on December 2, 2019.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit 99.1

   

Press Release, dated October 29, 2019.

Exhibit 104

    

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HCA HEALTHCARE, INC.

     

 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: October 29, 2019

EX-99.1 2 d826383dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO   LOGO

 

 

 

  FOR IMMEDIATE RELEASE
INVESTOR CONTACT:   MEDIA CONTACT:
Mark Kimbrough   Ed Fishbough
615-344-2688   615-344-2810

HCA Reports Third Quarter 2019 Results

Nashville, Tenn., October 29, 2019 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2019.

Key third quarter metrics (all percentage changes compare 3Q 2019 to 3Q 2018 unless otherwise noted):

 

  •  

Revenues totaled $12.694 billion

 

  •  

Net income attributable to HCA Healthcare, Inc. totaled $612 million, or $1.76 per diluted share

 

  •  

Adjusted EBITDA totaled $2.285 billion

 

  •  

Cash flows from operating activities totaled $2.126 billion

 

  •  

Same facility equivalent admissions and same facility admissions increased 4.2 percent and 3.2 percent, respectively

Revenues in the third quarter of 2019 increased to $12.694 billion, compared to $11.451 billion in the third quarter of 2018. Net income attributable to HCA Healthcare, Inc. totaled $612 million, or $1.76 per diluted share, compared to $759 million, or $2.15 per diluted share, in the third quarter of 2018. Results for the third quarter of 2019 include losses on retirement of debt of $211 million, or $0.47 per diluted share. Third quarter of 2018 results included gains on sales of facilities of $6 million, or $0.01 per diluted share, and losses on retirement of debt of $9 million, or $0.02 per diluted share.

For the third quarter of 2019, Adjusted EBITDA totaled $2.285 billion, compared to $2.096 billion in the third quarter of 2018. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions and equivalent admissions increased 3.2 percent and 4.2 percent, respectively, in the third quarter of 2019 compared to the prior year period. Same facility emergency room visits increased 4.1 percent in the third quarter of 2019, compared to the prior year period. Same facility inpatient surgeries increased 2.2 percent, and same facility outpatient surgeries increased 2.6 percent in the third quarter of 2019, compared to the same period of 2018. Same facility revenue per equivalent admission increased 2.0 percent in the third quarter of 2019, compared to the third quarter of 2018.

 

1

Salaries and benefits, supplies and other operating expenses totaled $10.413 billion, or 82.0 percent of revenues, in the third quarter of 2019, compared to $9.364 billion, or 81.8 percent of revenues, in the third quarter of 2018.

Nine Months Ended September 30, 2019

Revenues for the nine months ended September 30, 2019 totaled $37.813 billion, compared to $34.403 billion in the same period of 2018. Net income attributable to HCA Healthcare, Inc. was $2.434 billion, or $6.98 per diluted share, compared to $2.723 billion, or $7.65 per diluted share, for the first nine months of 2018. Results for the nine months ended September 30, 2019 include gains on sales of facilities of $17 million, or $0.04 per diluted share and losses on retirement of debt of $211 million, or $0.47 per diluted share. Results for the nine months ended September 30, 2018 included gains on sales of facilities of $420 million, or $0.89 per diluted share, and losses on retirement of debt of $9 million, or $0.02 per diluted share.

Balance Sheet and Cash Flows from Operations

As of September 30, 2019, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $559 million, total debt of $34.245 billion, and total assets of $43.912 billion. During the third quarter of 2019, capital expenditures totaled $1.139 billion, excluding acquisitions. Cash flows provided by operating activities in the third quarter totaled $2.126 billion, compared to $1.721 billion in the third quarter of 2018.

During the third quarter of 2019, the Company redeemed certain senior secured notes and recognized pretax losses on retirement of debt totaling $211 million, or $0.47 per diluted share, for these redemptions.

The Company repurchased 1.846 million shares of its common stock at a cost of $239 million during the third quarter of 2019. For the nine months ended September 30, 2019, the Company repurchased 5.880 million shares at a cost of $759 million. The Company had $1.513 billion remaining under its existing repurchase authorization as of the end of September 30, 2019.

Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share on the Company’s common stock. The dividend will be paid on December 27, 2019 to stockholders of record at the close of business on December 2, 2019.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

 

2

2019 Revised Guidance

The 2019 revised guidance ranges for the year are as follows:

 

    

2019 Guidance Range

Revenues

    $50.5 to $51.5 billion

Adjusted EBITDA

    $9.65 to $9.85 billion

EPS (diluted)

    $10.30 to $10.65 per diluted share

Capital Expenditures

    Approximately $3.8 billion

The Company’s 2019 guidance contains a number of assumptions, including:

 

  •  

2019 guidance includes an estimated financial impact of the Company’s Mission Health acquisition, which closed February 1, 2019.

 

  •  

2019 guidance excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claim costs and impairments of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Earnings Conference Call

HCA will host a conference call for investors at 9:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed at: https://event.webcasts.com/starthere.jsp?ei=1234730&tp_key=ab2d64f271 or through the Company’s Investor Relations web page at www.hcahealthcare.com.

About the Company

As of September 30, 2019, HCA operated 184 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 21 states and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2019, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties

 

3

and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (2) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Health Reform Law”), including the effects of court challenges to, any repeal of, or changes to, the Health Reform Law or additional changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, (3) the effects related to the continued implementation of the sequestration spending reductions required under the Budget Control Act of 2011, and related legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (4) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (5) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (6) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (7) the highly competitive nature of the health care business, (8) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (9) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (10) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (11) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (12) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (13) changes in accounting practices, (14) changes in general economic conditions nationally and regionally in our markets, (15) the emergence of and effects related to infectious diseases, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of potential cybersecurity incidents or security breaches, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology, (23) the impact of natural disasters, such as hurricanes and floods, or similar events beyond our control, (24) the effects of the 2017 Tax Cuts and Jobs Act, including potential legislation or interpretive guidance that may be issued by federal and state taxing authorities or other standard-setting bodies, and (25) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2018 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only

 

4

as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

5

HCA Healthcare, Inc.

Condensed Consolidated Comprehensive Income Statements

Third Quarter

(Dollars in millions, except per share amounts)

 

     2019     2018  
     Amount     Ratio     Amount     Ratio  

Revenues

    $ 12,694       100.0 %    $ 11,451       100.0 % 

Salaries and benefits

      5,971       47.0       5,377       46.9  

Supplies

      2,090       16.5       1,890       16.5  

Other operating expenses

      2,352       18.5       2,097       18.4  

Equity in earnings of affiliates

      (4 )      —         (9 )      (0.1 ) 

Depreciation and amortization

      647       5.1       582       5.1  

Interest expense

      448       3.5       442       3.9  

Gains on sales of facilities

      —         —         (6 )      (0.1 ) 

Losses on retirement of debt

      211       1.7       9       0.1  
  

 

 

    

 

 

    

 

 

    

 

 

  
     11,715       92.3       10,382       90.7  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

      979       7.7       1,069       9.3  

Provision for income taxes

      215       1.7       173       1.5  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

      764       6.0       896       7.8  

Net income attributable to noncontrolling interests

      152       1.2       137       1.2  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc.

    $ 612       4.8     $ 759       6.6  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted earnings per share

    $ 1.76       $ 2.15    

Shares used in computing diluted earnings per share (millions)

      347.487         353.639    

Comprehensive income attributable to HCA Healthcare, Inc.

    $ 582       $ 754    
  

 

 

      

 

 

    

 

6

HCA Healthcare, Inc.  
Condensed Consolidated Comprehensive Income Statements  
For the Nine Months Ended September 30, 2019 and 2018  

(Dollars in millions, except per share amounts)

 

  
     2019     2018  
     Amount     Ratio     Amount     Ratio  

Revenues

    $ 37,813       100.0 %    $ 34,403       100.0 % 

Salaries and benefits

      17,455       46.2       15,940       46.3  

Supplies

      6,249       16.5       5,722       16.6  

Other operating expenses

      7,013       18.6       6,325       18.5  

Equity in earnings of affiliates

      (23 )      (0.1 )      (25 )      (0.1 ) 

Depreciation and amortization

      1,902       4.9       1,697       4.9  

Interest expense

      1,386       3.7       1,309       3.8  

Gains on sales of facilities

      (17 )      —         (420 )      (1.2 ) 

Losses on retirement of debt

      211       0.6       9       —    
  

 

 

    

 

 

    

 

 

    

 

 

  
     34,176       90.4       30,557       88.8  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

      3,637       9.6       3,846       11.2  

Provision for income taxes

      765       2.0       702       2.1  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

      2,872       7.6       3,144       9.1  

Net income attributable to noncontrolling interests

      438       1.2       421       1.2  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc.

    $ 2,434       6.4     $ 2,723       7.9  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted earnings per share

    $ 6.98       $ 7.65    

Shares used in computing diluted earnings per share (millions)

      348.712         356.124    

Comprehensive income attributable to HCA Healthcare, Inc.

    $ 2,354       $ 2,735    
  

 

 

      

 

 

    

 

7

HCA Healthcare, Inc.

Condensed Consolidated Balance Sheets

(Dollars in millions)

 

     September 30,     June 30,     December 31,  
     2019     2019     2018  

ASSETS

       

Current assets:

       

Cash and cash equivalents

    $ 559     $ 2,430     $ 502  

Accounts receivable

      7,131       7,219       6,789  

Inventories

      1,769       1,826       1,732  

Other

      1,310       1,394       1,190  
  

 

 

    

 

 

    

 

 

  

Total current assets

      10,769       12,869       10,213  

Property and equipment, at cost

      46,295       45,369       42,965  

Accumulated depreciation

      (24,293 )      (23,902 )      (23,208 ) 
  

 

 

    

 

 

    

 

 

  
     22,002       21,467       19,757  

Investments of insurance subsidiaries

      357       342       362  

Investments in and advances to affiliates

      243       247       232  

Goodwill and other intangible assets

      8,160       8,140       7,953  

Right-of-use operating lease assets

      1,770       1,787       —    

Other

      611       597       690  
  

 

 

    

 

 

    

 

 

  
   $ 43,912     $ 45,449     $ 39,207  
  

 

 

    

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ DEFICIT

       

Current liabilities:

       

Accounts payable

    $ 2,610     $ 2,609     $ 2,577  

Accrued salaries

      1,669       1,497       1,580  

Other accrued expenses

      2,697       2,782       2,624  

Long-term debt due within one year

      148       2,073       788  
  

 

 

    

 

 

    

 

 

  

Total current liabilities

      7,124       8,961       7,569  

Long-term debt, less debt issuance costs and discounts of $244, $252 and $157

      34,097       34,120       32,033  

Professional liability risks

      1,349       1,354       1,275  

Right-of-use operating lease obligations

      1,440       1,460       —    

Income taxes and other liabilities

      1,349       1,324       1,248  

EQUITY (DEFICIT)

       

Stockholders’ deficit attributable to HCA Healthcare, Inc.

      (3,565 )      (3,902 )      (4,950 ) 

Noncontrolling interests

      2,118       2,132       2,032  
  

 

 

    

 

 

    

 

 

  

Total deficit

      (1,447 )      (1,770 )      (2,918 ) 
  

 

 

    

 

 

    

 

 

  
   $ 43,912     $ 45,449     $ 39,207  
  

 

 

    

 

 

    

 

 

  

 

8

HCA Healthcare, Inc.

Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2019 and 2018

(Dollars in millions)

 

     2019     2018  

Cash flows from operating activities:

     

Net income

    $ 2,872     $ 3,144  

Adjustments to reconcile net income to net cash provided by operating activities:

     

Increase (decrease) in cash from operating assets and liabilities:

     

Accounts receivable

      (93 )      (161 ) 

Inventories and other assets

      (95 )      (136 ) 

Accounts payable and accrued expenses

      (118 )      150  

Depreciation and amortization

      1,902       1,697  

Income taxes

      51       —    

Gains on sales of facilities

      (17 )      (420 ) 

Losses on retirement of debt

      211       9  

Amortization of debt issuance costs and discounts

      23       23  

Share-based compensation

      263       204  

Other

      98       76  
  

 

 

    

 

 

  

Net cash provided by operating activities

      5,097       4,586  
  

 

 

    

 

 

  

Cash flows from investing activities:

     

Purchase of property and equipment

      (2,884 )      (2,420 ) 

Acquisition of hospitals and health care entities

      (1,592 )      (1,056 ) 

Disposition of hospitals and health care entities

      49       802  

Change in investments

      35       65  

Other

      17       (6 ) 
  

 

 

    

 

 

  

Net cash used in investing activities

      (4,375 )      (2,615 ) 
  

 

 

    

 

 

  

Cash flows from financing activities:

     

Issuance of long-term debt

      6,451       2,000  

Net change in revolving credit facilities

      (30 )      (330 ) 

Repayment of long-term debt

      (5,289 )      (1,652 ) 

Distributions to noncontrolling interests

      (404 )      (315 ) 

Payment of debt issuance costs

      (71 )      (24 ) 

Payment of cash dividends

      (414 )      (366 ) 

Repurchase of common stock

      (759 )      (1,195 ) 

Other

      (145 )      (232 ) 
  

 

 

    

 

 

  

Net cash used in financing activities

      (661 )      (2,114 ) 
  

 

 

    

 

 

  

Effect of exchange rate changes on cash and cash equivalents

      (4 )      (11 ) 
  

 

 

    

 

 

  

Change in cash and cash equivalents

      57       (154 ) 

Cash and cash equivalents at beginning of period

      502       732  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 559     $ 578  
  

 

 

    

 

 

  

Interest payments

    $ 1,492     $ 1,422  

Income tax payments, net

    $ 714     $ 702  

 

9

HCA Healthcare, Inc.

Operating Statistics

   
     Third Quarter     For the Nine Months
Ended September 30,		  
     2019     2018     2019     2018  

Operations:

         

Number of Hospitals

      184       179       184       179  

Number of Freestanding Outpatient Surgery Centers

      125       122       125       122  

Licensed Beds at End of Period

      48,588       47,060       48,588       47,060  

Weighted Average Licensed Beds

      48,535       46,909       48,335       46,755  

Reported:

         

Admissions

      527,284       497,899       1,568,733       1,500,382  

% Change

      5.9 %        4.6 %   

Equivalent Admissions

      918,964       854,940       2,712,339       2,555,151  

% Change

      7.5 %        6.2 %   

Revenue per Equivalent Admission

    $ 13,814     $ 13,394     $ 13,941     $ 13,464  

% Change

      3.1 %        3.5 %   

Inpatient Revenue per Admission

    $ 14,192     $ 13,642     $ 14,297     $ 13,716  

% Change

      4.0 %        4.2 %   

Patient Days

      2,530,221       2,391,127       7,667,666       7,293,152  

% Change

      5.8 %        5.1 %   

Equivalent Patient Days

      4,410,715       4,106,404       13,257,395       12,420,238  

% Change

      7.4 %        6.7 %   

Inpatient Surgery Cases

      143,215       137,156  *      421,051       409,595  * 

% Change

      4.4 %        2.8 %   

Outpatient Surgery Cases

      249,177       236,801  *      743,464       715,297  * 

% Change

      5.2 %        3.9 %   

Emergency Room Visits

      2,269,364       2,139,375       6,810,141       6,589,825  

% Change

      6.1 %        3.3 %   

Outpatient Revenues as a Percentage of Patient Revenues

      39.0 %      38.7 %      38.7 %      38.2 % 

Average Length of Stay (days)

      4.799       4.802       4.888       4.861  

Occupancy

      56.7 %      55.4 %      58.1 %      57.1 % 

Same Facility:

         

Admissions

      499,436       483,772       1,489,878       1,458,567  

% Change

      3.2 %        2.1 %   

Equivalent Admissions

      862,526       827,734       2,553,651       2,479,564  

% Change

      4.2 %        3.0 %   

Revenue per Equivalent Admission

    $ 13,721     $ 13,451     $ 13,858     $ 13,501  

% Change

      2.0 %        2.6 %   

Inpatient Revenue per Admission

    $ 14,243     $ 13,661     $ 14,344     $ 13,733  

% Change

      4.3 %        4.4 %   

Inpatient Surgery Cases

      135,379       132,509       398,215       395,679  

% Change

      2.2 %        0.6 %   

Outpatient Surgery Cases

      235,853       229,825       705,699       694,783  

% Change

      2.6 %        1.6 %   

Emergency Room Visits

      2,161,245       2,075,219       6,500,579       6,399,026  

% Change

      4.1 %        1.6 %   

 

*

Reclassifications between inpatient surgery cases and outpatient surgery cases for 2018 have been made to conform to the 2019 presentation.

 

10

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

Operating Results Summary

(Dollars in millions, except per share amounts)

 

     Third Quarter     For the Nine Months
Ended September 30,		  
     2019     2018     2019     2018  

Revenues

    $ 12,694     $ 11,451     $ 37,813     $ 34,403  

Net income attributable to HCA Healthcare, Inc.

    $ 612     $ 759     $ 2,434     $ 2,723  

Gains on sales of facilities (net of tax)

      —         (5 )      (13 )      (318 ) 

Losses on retirement of debt (net of tax)

      162       7       162       7  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt (a)

      774       761       2,583       2,412  

Depreciation and amortization

      647       582       1,902       1,697  

Interest expense

      448       442       1,386       1,309  

Provision for income taxes

      264       174       810       602  

Net income attributable to noncontrolling interests

      152       137       438       421  
  

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA (a)

    $ 2,285     $ 2,096     $ 7,119     $ 6,441  
  

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA margin (a)

      18.0 %      18.3 %      18.8 %      18.7 % 

Diluted earnings per share:

         

Net income attributable to HCA Healthcare, Inc.

    $ 1.76     $ 2.15     $ 6.98     $ 7.65  

Gains on sales of facilities

      —         (0.01 )      (0.04 )      (0.89 ) 

Losses on retirement of debt

      0.47       0.02       0.47       0.02  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt (a)

    $ 2.23     $ 2.16     $ 7.41     $ 6.78  
  

 

 

    

 

 

    

 

 

    

 

 

  

Shares used in computing diluted earnings per share (millions)

      347.487       353.639       348.712       356.124  

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that gains on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

11

HCA Healthcare, Inc.

Supplemental Non-GAAP Disclosures

2019 Operating Results Forecast

(Dollars in millions, except per share amounts)

 

     For the Year Ending
December 31, 2019		  
     Low      High  

Revenues

    $ 50,500      $ 51,500  

Net income attributable to HCA Healthcare, Inc. (a)

    $ 3,595      $ 3,720  

Depreciation and amortization

      2,550        2,575  

Interest expense

      1,825        1,850  

Provision for income taxes

      1,090        1,115  

Net income attributable to noncontrolling interests

      590        590  
  

 

 

     

 

 

  

Adjusted EBITDA (a) (b)

    $ 9,650      $ 9,850  
  

 

 

     

 

 

  

Diluted earnings per share:

      

Net income attributable to HCA Healthcare, Inc.

    $ 10.30      $ 10.65  

Shares used in computing diluted earnings per share (millions)

      349.200        349.200  

The Company’s forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.

 

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

 

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (“GAAP”). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

12

EX-101.SCH 3 hca-20191029.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20191029_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20191029_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g8263831.jpg GRAPHIC begin 644 g8263831.jpg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end GRAPHIC 7 g8263832.jpg GRAPHIC begin 644 g8263832.jpg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end ZIP 8 0001193125-19-277113-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-277113-xbrl.zip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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 d826383d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2019-10-29 2019-10-29 false 0000860730 8-K 2019-10-29 HCA HEALTHCARE, INC. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document and Entity Information
Oct. 29, 2019
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000860730
Document Type 8-K
Document Period End Date Oct. 29, 2019
Entity Registrant Name HCA HEALTHCARE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-11239
Entity Tax Identification Number 27-3865930
Entity Address, Address Line One One Park Plaza
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code (615)
Local Phone Number 344-9551
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $.01 par value per share
Trading Symbol HCA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d826383d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d826383d8k.htm" ] }, "labelLink": { "local": [ "hca-20191029_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hca-20191029_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hca-20191029.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hca", "nsuri": "http://www.hcahealthcare.com/20191029", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d826383d8k.htm", "contextRef": "duration_2019-10-29_to_2019-10-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d826383d8k.htm", "contextRef": "duration_2019-10-29_to_2019-10-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.hcahealthcare.com//20191029/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d826383d8k.htm d826383dex991.htm hca-20191029.xsd hca-20191029_lab.xml hca-20191029_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false